News & insights
VA Webinar, January 23rd 2026, Is your value story working hard enough?
Join our expert speakers to explore how to optimise your product value story and use it to drive market access, from early modelling to HTA submission.
ISPOR Europe 2025 9-12 November
The Visible Analytics team will be in Glasgow this November and we look forward to meeting you there.
Come meet us at our booth #920 and join us at one of our sessions.
World Sickle Cell Day 2025
What can we learn from the recent NICE appraisal of bew groundbreaking gene therapy for sickle cell disorder (SCD), and how can we use these insights to better shape reimbursement and market access for patients with SCD and other underserved or rare conditions?
World Congress EPA 2025 5-6 March
The Visible Analytics team is excited to exhibit, present, and engage at the World Evidence, Pricing and Access Congress 2025 in Amsterdam. Join us and learn how we use strategic insights and expert analytics to help pharmaceutical and medical device companies navigate our changing and challenging HTA landscapes.
VA Webinar, November 6th 2024, Use of Real-World Evidence in HTA
Join us for an engaging webinar to explore the transformative power of RWE in HTA and how it’s driving better healthcare decisions and patient outcomes.
ISPOR Europe 2024 17-20 November
The Visible Analytics team will be in Barcelona and looks forward to meeting you there.
Come meet us at our booth 1506 and join us at one of our sessions.
VA Webinar, February 14th 2024, HTA methods to optimize evidence generation plans
Visible Analytics will be co-hosting a live webinar with Ascenian to discuss how HTA methods and early value assessment can help companies prepare for evidence generation and early market access strategy.
ISPOR Europe 2023 12-15 November
The Visible Analytics team will be in Copenhagen and looks forward to meeting you there.
Come meet us at our booth C3-046 and join us at one of our sessions.
VA Webinar, July 27th 2021, RWE in HTA
Recent advances in analytical methods for combining evidence from RCTs and non-RCTs, and the development of new frameworks for the inclusion of RWE in HTA have provided a greater insight on how issues around RWE uncertainty can be dealt with ....
